BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 26847329)

  • 21. Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas.
    Galic V; Willner J; Wollan M; Garg R; Garcia R; Goff BA; Gray HJ; Swisher EM
    Genes Chromosomes Cancer; 2007 Mar; 46(3):239-47. PubMed ID: 17171684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making.
    Jorge S; McFaddin AS; Doll KM; Pennington KP; Norquist BM; Bennett RL; Pritchard CC; Swisher EM
    Gynecol Oncol; 2020 Mar; 156(3):517-522. PubMed ID: 31883735
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted Genomic Sequencing Reveals Novel
    Jung YY; Woo HY; Kim HS
    Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RE: PPM1D mutations in circulating white blood cells and the risk for ovarian cancer.
    Qiu H
    J Natl Cancer Inst; 2014 Apr; 106(4):dju045. PubMed ID: 24634502
    [No Abstract]   [Full Text] [Related]  

  • 25. Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing.
    Cole AJ; Dwight T; Gill AJ; Dickson KA; Zhu Y; Clarkson A; Gard GB; Maidens J; Valmadre S; Clifton-Bligh R; Marsh DJ
    Sci Rep; 2016 May; 6():26191. PubMed ID: 27189670
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.
    Brachova P; Mueting SR; Carlson MJ; Goodheart MJ; Button AM; Mott SL; Dai D; Thiel KW; Devor EJ; Leslie KK
    Int J Oncol; 2015 Feb; 46(2):607-18. PubMed ID: 25385265
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity.
    Bulavin DV; Demidov ON; Saito S; Kauraniemi P; Phillips C; Amundson SA; Ambrosino C; Sauter G; Nebreda AR; Anderson CW; Kallioniemi A; Fornace AJ; Appella E
    Nat Genet; 2002 Jun; 31(2):210-5. PubMed ID: 12021785
    [TBL] [Abstract][Full Text] [Related]  

  • 28. WIP1 phosphatase as a potential therapeutic target in neuroblastoma.
    Richter M; Dayaram T; Gilmartin AG; Ganji G; Pemmasani SK; Van Der Key H; Shohet JM; Donehower LA; Kumar R
    PLoS One; 2015; 10(2):e0115635. PubMed ID: 25658463
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Significance of the Wild Type p53-Induced Phosphatase 1 Expression in Invasive Breast Cancer.
    Inoue Y; Yamashita N; Kitao H; Tanaka K; Saeki H; Oki E; Oda Y; Tokunaga E; Maehara Y
    Clin Breast Cancer; 2018 Aug; 18(4):e643-e650. PubMed ID: 29275106
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Truncating and missense PPM1D mutations in early-onset and/or familial/hereditary prostate cancer patients.
    Cardoso M; Paulo P; Maia S; Teixeira MR
    Genes Chromosomes Cancer; 2016 Dec; 55(12):954-961. PubMed ID: 27401275
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inherited Mutations in Women With Ovarian Carcinoma.
    Norquist BM; Harrell MI; Brady MF; Walsh T; Lee MK; Gulsuner S; Bernards SS; Casadei S; Yi Q; Burger RA; Chan JK; Davidson SA; Mannel RS; DiSilvestro PA; Lankes HA; Ramirez NC; King MC; Swisher EM; Birrer MJ
    JAMA Oncol; 2016 Apr; 2(4):482-90. PubMed ID: 26720728
    [TBL] [Abstract][Full Text] [Related]  

  • 32. miR-7 expression in serous ovarian carcinomas.
    Swiercz A; Chechlinska M; Kupryjanczyk J; Dansonka-Mieszkowska A; Rembiszewska A; Goryca K; Kulinczak M; Zajdel M; Sromek M; Siwicki JK
    Anticancer Res; 2015 Apr; 35(4):2423-9. PubMed ID: 25862909
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative analysis of loss of heterozygosity of specific chromosome 3, 13, 17, and X loci and TP53 mutations in human epithelial ovarian cancer.
    Manderson EN; Presneau N; Provencher D; Mes-Masson AM; Tonin PN
    Mol Carcinog; 2002 Jun; 34(2):78-90. PubMed ID: 12112314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Akt confers cisplatin chemoresistance in human gynecological carcinoma cells by modulating PPM1D stability.
    Ali AY; Kim JY; Pelletier JF; Vanderhyden BC; Bachvarov DR; Tsang BK
    Mol Carcinog; 2015 Nov; 54(11):1301-14. PubMed ID: 25154814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of Novel Somatic
    Garziera M; Cecchin E; Canzonieri V; Sorio R; Giorda G; Scalone S; De Mattia E; Roncato R; Gagno S; Poletto E; Romanato L; Sartor F; Polesel J; Toffoli G
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29783665
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Arsenic Trioxide Promotes Paclitaxel Cytotoxicity in Resistant Breast Cancer Cells.
    Bakhshaiesh TO; Armat M; Shanehbandi D; Sharifi S; Baradaran B; Hejazi MS; Samadi N
    Asian Pac J Cancer Prev; 2015; 16(13):5191-7. PubMed ID: 26225652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Truncated PPM1D impairs stem cell response to genotoxic stress and promotes growth of APC-deficient tumors in the mouse colon.
    Burocziova M; Burdova K; Martinikova AS; Kasparek P; Kleiblova P; Danielsen SA; Borecka M; Jenikova G; Janečková L; Pavel J; Zemankova P; Schneiderova M; Schwarzova L; Ticha I; Sun XF; Jiraskova K; Liska V; Vodickova L; Vodicka P; Sedlacek R; Kleibl Z; Lothe RA; Korinek V; Macurek L
    Cell Death Dis; 2019 Oct; 10(11):818. PubMed ID: 31659152
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach.
    Garziera M; Roncato R; Montico M; De Mattia E; Gagno S; Poletto E; Scalone S; Canzonieri V; Giorda G; Sorio R; Cecchin E; Toffoli G
    Cells; 2019 Jun; 8(6):. PubMed ID: 31197119
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A small molecule inhibitor of p53-inducible protein phosphatase PPM1D.
    Yagi H; Chuman Y; Kozakai Y; Imagawa T; Takahashi Y; Yoshimura F; Tanino K; Sakaguchi K
    Bioorg Med Chem Lett; 2012 Jan; 22(1):729-32. PubMed ID: 22115592
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The serine-threonine protein phosphatase PPM1D is frequently activated through amplification in aggressive primary breast tumours.
    Rauta J; Alarmo EL; Kauraniemi P; Karhu R; Kuukasjärvi T; Kallioniemi A
    Breast Cancer Res Treat; 2006 Feb; 95(3):257-63. PubMed ID: 16254685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.